These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31294079)

  • 1. Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis.
    Raccah D; Guerci B; Ajmera M; Davis K; Meyers J; Lew E; Shaunik A; Blonde L
    Endocrinol Diabetes Metab; 2019 Jul; 2(3):e00061. PubMed ID: 31294079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin.
    Buysman EK; Fan T; Blauer-Peterson C; Miller-Wilson LA
    Endocrinol Diabetes Metab; 2018 Jul; 1(3):e00019. PubMed ID: 30815554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care.
    Bieszk N; Grabner M; Wei W; Barron J; Quimbo R; Yan T; Biel B; Chu JW
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1160-1168. PubMed ID: 29083969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
    Ruiz-Negrón N; Wander C; McAdam-Marx C; Pesa J; Bailey RA; Bellows BK
    J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
    Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
    Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
    Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
    Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
    Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.
    Lang K; Nguyen H; Huang H; Bauer E; Levin P
    Curr Med Res Opin; 2018 Jun; 34(6):1045-1051. PubMed ID: 29394878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.
    Peng XV; McCrimmon RJ; Shepherd L; Boss A; Lubwama R; Dex T; Skolnik N; Ji L; Avogaro A; Blonde L
    Diabetes Ther; 2020 Nov; 11(11):2629-2645. PubMed ID: 32902774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting.
    McAdam-Marx C; Bouchard J; Aagren M; Nelson R; Brixner D
    Diabetes Obes Metab; 2010 Jan; 12(1):54-64. PubMed ID: 19758356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.
    McCrimmon RJ; Cheng AYY; Galstyan G; Djaballah K; Li X; Coudert M; Frias JP
    Diabetes Obes Metab; 2023 Jan; 25(1):68-77. PubMed ID: 36123617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model.
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Kong SX; Ji X; Ganguly R; Milinovich A; Weng W; Bauman JM; Petraro P; Burguera B; Zimmerman RS; Kattan MW
    Diabetes Care; 2020 Aug; 43(8):1910-1919. PubMed ID: 32527797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.